Trade Dynavax Technologies

Dynavax is a commercial phase biopharmaceutical company developing and marketing new vaccines. The company launched HEPLISAV-B® [Hepatitis B Vaccine, Adjuvant], its first commercial product, in February 2018, after approval by the U.S. Food and Drug Administration to prevent infection sought by all known subtypes of hepatitis B virus in adults 18 years and older. Dynavax is an equal opportunity employer and prohibits unlawful discrimination on the basis of race, colour, religion, sex, sexual orientation, gender/gender expression, national origin/descent, age, disability, military status and veterans.